Anagliptin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anagliptin
Anagliptin.svg
Systematic (IUPAC) name
N-[2-[[2-[(2S)-2-Cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
Clinical data
Trade names Suiny
Legal status
  • Approved in Japan
Routes of
administration
Oral
Identifiers
CAS Registry Number 739366-20-2
ATC code None
ChemSpider 28492667
Chemical data
Formula C19H25N7O2
Molecular mass 383.45 g/mol

Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan.[1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[2]

References[edit]

  1. ^ A.I. Graul, B. Lupone, E. Cruces and M. Stringer (2013). "2012 in Review - Part I: The Year's New Drugs and Biologics" (PDF). Drugs of Today 49 (1): 33–68. doi:10.1358/dot.2013.49.1.1933991. 
  2. ^ Kato, Noriyasu; Oka, Mitsuru; Murase, Takayo; Yoshida, Masahiro; Sakairi, Masao; Yamashita, Satoko; Yasuda, Yoshika; Yoshikawa, Aya; Hayashi, Yuuji; Makino, Mitsuhiro; Takeda, Motohiro; Mirensha, Yakufu; Kakigami, Takuji (2011). "Discovery and pharmacological characterization of N-\2-({2-\(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo\1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor". Bioorganic & Medicinal Chemistry 19 (23): 7221. doi:10.1016/j.bmc.2011.09.043.